NNC 0519 0130
Alternative Names: NNC-0519-0130Latest Information Update: 25 Jul 2024
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 18 Jul 2024 Novo Nordisk plans a phase pharmacokinetics I trial (In adults, In volunteers) in Germany (SC) (NCT06513104) in July 2024
- 15 Apr 2024 Novo Nordisk initiates a phase I pharmacokinetics trial in Type 2 diabetes mellitus (In volunteers) in Germany (SC) (NCT06370819)
- 02 Apr 2024 Novo Nordisk completes a phase I trial in Obesity (In volunteers) in Denmark, Germany (PO) (NCT05363774)